menu
    • menu
    [{"orgOrder":0,"company":"Entero Healthcare Solutions","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved","graph3":"Entero Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Entero Healthcare Solutions \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Entero Healthcare Solutions \/ Roche"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Azathioprine","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Corticosteroid","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Inbakicept","moa":"IL-15","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Mycophenolate Mofetil

    Menu

    Mycophenolate Mofetil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides Pharma Arm Gets USFDA Nod for Generic Mycophenolate Mofetil Oral Suspension

                            Details : Mycophenolate mofetil is an immunosuppressive agent act as the inosine monophosphate dehydrogenase (IMPDH) inhibitor, which is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

                            Brand Name : CellCept-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Azurity Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Announces FDA Approval Of Myhibbin™ Oral Suspension

                            Details : Myhibbin (mycophenolate mofetil) is an immunosuppressive agent acting as an inosine monophosphate dehydrogenase (IMPDH) inhibitor, indicated for preventing organ rejection in transplant patients.

                            Brand Name : Myhibbin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2024

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupu...

                            Details : Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being develope...

                            Brand Name : Lupkynis

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 11, 2023

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for Lupkynis® in the Tr...

                            Details : Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being develope...

                            Brand Name : Lupkynis

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurinia Presents Results From the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association ...

                            Details : LUPKYNIS (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the k...

                            Brand Name : Lupkynis

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 20, 2022

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress

                            Details : LUPKYNIS (voclosporin) is first FDA-approved structurally modified calcineurin inhibitor for treatment of patients with active lupus nephritis, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production.

                            Brand Name : Lupkynis

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meeting...

                            Details : Lupkynis (voclosporin), is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the ...

                            Brand Name : Lupkynis

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 04, 2022

                            Lead Product(s) : Voclosporin,Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ImmunityBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ImmunityBio

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inbakicept,Tacrolimus,Mycophenolate Mofetil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support Immuni...

                            Details : Study demonstrated that NK cells when stimulated with a cytokine cocktail developed a memory-like phenotype with increased expansion and persistence in vivo, as a treatment for cancer of its m-ceNK platform combined with IL-15 superagonist cytokine fusio...

                            Brand Name : Anktiva

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Inbakicept,Tacrolimus,Mycophenolate Mofetil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iscalimab,Mycophenolate Mofetil,Corticosteroid

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novartis Halts Study of Iscalimab in Kidney Transplant Patients

                            Details : The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.

                            Brand Name : CFZ533

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 03, 2021

                            Lead Product(s) : Iscalimab,Mycophenolate Mofetil,Corticosteroid

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-1273,Mycophenolate Mofetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            COVID-19 Vaccine Clinical Trial in People With Autoimmune Disease Starts at Feinstein Institutes

                            Details : The “COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders” trial will study the antibody response to an extra shot of an authorized or approved COVID-19 vaccine in people with an autoimmune disease whose body did not respond to an original v...

                            Brand Name : mRNA-1273

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 02, 2021

                            Lead Product(s) : mRNA-1273,Mycophenolate Mofetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth